Synexus Acquires Research Across America
The addition of Research Across America's sites means that Synexus can now offer extra capacity, particular U.S. market expertise and therapeutic experience.
Synexus has purchased Research Across America (RAA) for an undisclosed sum. RAA was founded in 1989 by Dr. Jeffrey Adelglass, and has grown from a single location to multiple dedicated research sites across the U.S. Its sites have conducted over 2,000 clinical trials.
Synexus already owns 25 research sites in 10 countries. The addition of RAA’s sites means that it can now offer extra capacity, particular U.S. market expertise and therapeutic experience.
“Synexus already has a strong international footprint. This latest acquisition is an important one for Synexus as it marks our entry into the US market, giving us truly global capability,” noted CEO Christophe Berthoux. “We spent a great deal of time considering an appropriate partner and selected Research Across America as it has a number of synergies with the Synexus model. In addition, by adding these sites to our network we have also gained expertise in areas, such as dermatology and generics, enabling us to further support our client base.”
Read the full article.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
